Division of Cardiovascular Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California; Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.
Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.
J Heart Lung Transplant. 2023 Oct;42(10):1415-1424. doi: 10.1016/j.healun.2023.05.008. Epub 2023 May 20.
The 2018 adult heart allocation policy sought to improve waitlist risk stratification, reduce waitlist mortality, and increase organ access. This system prioritized patients at greatest risk for waitlist mortality, especially individuals requiring temporary mechanical circulatory support (tMCS). Posttransplant complications are significantly higher in patients on tMCS before transplantation, and early posttransplant complications impact long-term mortality. We sought to determine if policy change affected early posttransplant complication rates of rejection, infection, and hospitalization.
We included all adult, heart-only, single-organ heart transplant recipients from the UNOS registry with pre-policy (PRE) individuals transplanted between November 1, 2016, and October 31, 2017, and post-policy (POST) between November 1, 2018, and October 31, 2019. We used a multivariable logistic regression analysis to assess the effect of policy change on posttransplant rejection, infection, and hospitalization. Two COVID-19 eras (2019-2020, 2020-2021) were included in our analysis.
The majority of baseline characteristics were comparable between PRE and POST era recipients. The odds of treated rejection (p = 0.8), hospitalization (p = 0.69), and hospitalization due to rejection (p = 0.76) and infection (p = 0.66) were similar between PRE and POST eras; there was a trend towards reduced odds of rejection (p = 0.08). In both COVID eras, there was a clear reduction in rejection and treated rejection with no effect on hospitalization for rejection or infection. Odds of all-cause hospitalization was increased in both COVID eras.
The UNOS policy change improves access to heart transplantation for higher acuity patients without increasing early posttransplant rates of treated rejection or hospitalization for rejection or infection, factors which portend risk for long-term posttransplant mortality.
2018 年成人心脏分配政策旨在改善等待名单风险分层,降低等待名单死亡率,并增加器官获取。该系统优先考虑等待名单死亡率最高的患者,特别是需要临时机械循环支持(tMCS)的患者。移植前接受 tMCS 的患者移植后并发症明显更高,早期移植后并发症会影响长期死亡率。我们试图确定政策变化是否会影响排斥反应、感染和住院治疗的早期移植后并发症发生率。
我们纳入了 UNOS 登记处的所有成人、心脏-only、单一器官心脏移植受者,包括预政策(PRE)个体,他们于 2016 年 11 月 1 日至 2017 年 10 月 31 日移植,以及后政策(POST)个体,他们于 2018 年 11 月 1 日至 2019 年 10 月 31 日移植。我们使用多变量逻辑回归分析来评估政策变化对移植后排斥反应、感染和住院治疗的影响。我们的分析包括了两个 COVID-19 时期(2019-2020 年,2020-2021 年)。
PRE 和 POST 时期受者的大多数基线特征相似。接受治疗的排斥反应(p=0.8)、住院治疗(p=0.69)、因排斥反应(p=0.76)和感染(p=0.66)住院的几率在 PRE 和 POST 时期相似;排斥反应的几率有下降趋势(p=0.08)。在两个 COVID 时期,排斥反应和治疗性排斥反应的发生率均明显降低,而排斥反应和感染导致的住院治疗率没有影响。两个 COVID 时期全因住院的几率都增加了。
UNOS 政策的改变改善了对更高危患者进行心脏移植的机会,而不会增加治疗性排斥反应或因排斥反应或感染而导致的住院治疗的早期移植后发生率,这些因素预示着长期移植后死亡率的风险。